Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:

NCT ID: NCT04830345 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines

Start date: June 29, 2020
Phase: Phase 3
Study type: Interventional

Efficacy and safety of ATGC-100 are assessed in subjects with moderate to severe glabellar lines.

NCT ID: NCT04715048 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Split-Face Study Comparing Botox and Jeuveau in Treating Glabellar Lines

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to compare the efficacy and side effects of Botox and Jeuveau for glabellar lines.

NCT ID: NCT04281745 Active, not recruiting - Clinical trials for Glabellar Frown Lines

Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®

Start date: October 17, 2019
Phase: Phase 4
Study type: Interventional

This study evaluates the long-term safety and efficacy of CORETOX in the treatment of moderate to severe glabellar lines.

NCT ID: NCT04281095 Completed - Clinical trials for Glabellar Frown Lines

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines

Start date: November 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Botox for a total of 12 weeks after the administration in treatment of glabellar frown lines.

NCT ID: NCT04249583 Completed - Clinical trials for Glabellar Frown Lines

Treatment of Moderate to Severe Glabellar Lines

READY-1
Start date: February 10, 2020
Phase: Phase 3
Study type: Interventional

The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.

NCT ID: NCT04143815 Completed - Clinical trials for Glabellar Frown Lines

Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines

Start date: May 20, 2019
Phase: Phase 2
Study type: Interventional

This study will determine the effect of MBA-P01 in subjects with glabellar lines at a range of doses compared with placebo. This study includes two treatment period; 1) Dose-ranging period, Day0 to 16weeks and 2) Open-label extension period, 16 weeks to 52.

NCT ID: NCT03985982 Completed - Clinical trials for Glabellar Frown Lines

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

BLESSIII
Start date: April 29, 2019
Phase: Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.

NCT ID: NCT03960957 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines

Start date: June 17, 2019
Phase: Phase 3
Study type: Interventional

An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines

NCT ID: NCT03908008 Completed - Clinical trials for Glabellar Frown Lines

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

Start date: January 2014
Phase: Phase 3
Study type: Interventional

This study design is a parallel, active drug controlled, double blind, randomized, multi-centered, phase III clinical trial to compare the efficacy and safety of MT10107 versus BOTOX® in treatment of glabella line.

NCT ID: NCT03837561 Completed - Clinical trials for Glabellar Frown Lines

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

Start date: December 13, 2018
Phase: Phase 3
Study type: Interventional

To Confirm the non-inferiority of CUNOX® to BOTOX® in the glabellar line improvement of moderate to severe glabellar lines.